Alterome Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that members of its management team will participate in one-on-one investor meetings at the following upcoming conferences:

• TD Cowen 46th Annual Health Care Conference, taking place March 2–4, 2026 in Boston, MA
• Leerink Partners 2026 Global Healthcare Conference, taking place March 8–11, 2026 in Miami, FL

About Alterome Therapeutics

Alterome Therapeutics, Inc. is a clinical-stage precision oncology biotechnology company developing alteration-specific therapeutics to address high-value and validated oncogenic drivers. Our pipeline includes two Phase 1 therapies in development for solid tumors: ALTA2618, a first-in-class, oral mutation-selective inhibitor for AKT1 E17K-driven cancers, and ALTA3263, a first-in-class, oral pan-KRAS inhibitor designed to shut down KRAS activity in both ON and OFF states. Alterome has raised more than $231 million in venture capital to date and is led by a team of precision oncology R&D leaders with a history of successfully developing oncology small molecule drugs.

For more information, visit www.alterome.com and follow us on LinkedIn.

Investors:
Scott Moorefield
Alterome Therapeutics
investors@alterome.com

Media:
Michael Galfetti
Ten Bridge Communications
alterome@tenbridgescommunications.com